All News

Lilly Announces FDA Approval of Lebrikizumab-lbkz for Moderate to Severe Atopic Dermatitis
September 16, 2024

Among those treated with lebrikizumab, more than one-third saw clear/almost clear skin at week 16; three-quarters of them maintained results at week 52 with monthly dosing.

Investigational PACAP Inhibitor Reduces Monthly Migraine Days, Lundbeck Reports
September 16, 2024

Individuals with migraine who failed to respond to up to 4 previous migraine preventive treatments saw fewer monthly migraine and headache days after 1 infusion of Lu AG90222.

Axsome Therapeutics: FDA Accepts NDA Resubmission for AXS-07 for Acute Treatment of Migraine
September 16, 2024

Based on its acceptance of the resubmission, FDA has assigned a PDUFA action goal date of January 31, 2025 for AXS-07.

FDA Approves Dupilumab Label Expansion with Indication for CRSwNP in Adolescents
September 13, 2024

The approval makes dupilumab available to treat uncontrolled CRSwNP in adolescents aged 12 to 17 years, expanding on the current approved range of 18 years and older.

Awareness of Uncontrolled Hypertension Low, Particularly Among Young Adults, Study Warns
September 13, 2024

Unawareness was highest among the youngest adults, aged 18 to 44 years, an age range where CV health should be optimized to avoid later morbidity, researchers wrote.

Atrial Fibrillation in the US 3-Fold More Prevalent Than Previously Estimated, New Data Suggest
September 13, 2024

Approximately 10.5 million US adults, or 5% of the population, have the atrial fibrillation, according to new prevalence estimates.

How to Define an Atopic Dermatitis Flare: Survey Seeks New Patient Consensus
September 12, 2024

The term "flare" is used consistently in discussions of AD, but is everyone talking about the same thing? New research closes in on a patient-centered definition.

Best States for Health Care in the US: 2024
September 12, 2024

Which state retains the most medical residents? Or has the lowest cancer rate? Answers and more insights from a nationwide analysis, here.

GSK mRNA Flu Vaccine Candidate Delivers Favorable Topline Phase 2 Findings, Ready for Phase 3
September 12, 2024

The GSK reformulation induced acceptable immune responses for both influenza A and B strains, overcoming a setback earlier in the ability to successfully neutralize the latter.

Statin Plus Ezetimibe Outperforms High-Dose Statins in LDL-C Reduction: Daily Dose
September 12, 2024

Your daily dose of the clinical news you may have missed.